Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03180294 · OUTCOME

Change From Baseline in the PROMIS Global Satisfaction With Sex Life Subscore of Sexual Function and Satisfaction Measure ("Sexual Desire and Satisfaction")

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer · Source last updated 2026-07-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
units on a scale
Interval / dispersion
Standard Deviation
Time frame
Baseline (prior to randomization) and 5 and 9 weeks from start of study treatment (within 21 days of randomization)

What was measured

The PROMIS Global Satisfaction with Sex Life subscore measures self-reported global satisfaction, interest, and interference in sexual health over the past 7 days. Possible scores range from 3 to 30, with higher scores indicating more satisfaction with sex life. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased satisfaction. This score is referred to as the "PROMIS sexual desire and satisfaction measure" in the protocol.

Analysis population: Eligible with baseline data

Groups in this outcome

Bupropion 150 mg

One Bupropion 150 mg XL capsule PO in a.m. daily for one week; one Bupropion 150 mg XL capsule and one placebo capsule PO in a.m. daily for 8 weeks; one placebo capsule daily PO in a.m. for one 1 week (titration off).

Bupropion 300 mg

One Bupropion 150 mg XL capsule PO in a.m. daily for one week; two Bupropion 150 mg XL capsules PO in a.m. daily for 8 weeks (300 mg target dose); one Bupropion 150 mg XL capsule PO in a.m. daily for 1 week (titration off)

Placebo

One placebo capsule PO in a.m. daily for 1 week; two placebo capsules PO in a.m. daily for 8 weeks; one placebo capsule PO in a.m. daily for 1 week (titration off)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bupropion 150 mg79
Bupropion 300 mg74
Placebo76

Reported measurements

Week 5

Analysis denominator · Participants

GroupSource count
Bupropion 150 mg65
Bupropion 300 mg59
Placebo61
Values in units on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Bupropion 150 mg3.357.27Not reportedNot reportedNot reported
Bupropion 300 mg2.815.82Not reportedNot reportedNot reported
Placebo3.086.00Not reportedNot reportedNot reported
Week 9

Analysis denominator · Participants

GroupSource count
Bupropion 150 mg65
Bupropion 300 mg60
Placebo60
Values in units on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Bupropion 150 mg2.056.51Not reportedNot reportedNot reported
Bupropion 300 mg2.724.72Not reportedNot reportedNot reported
Placebo3.586.93Not reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. group Description
    Week 5
    group Ids
    1. OG000
    2. OG002
    non Inferiority Type
    SUPERIORITY
    p Value
    0.41
    p Value Comment
    One-sided significance level 0.05
    statistical Method
    t-test, 1 sided
  2. group Description
    Week 5
    group Ids
    1. OG001
    2. OG002
    non Inferiority Type
    SUPERIORITY
    p Value
    0.60
    p Value Comment
    One-sided significance level 0.05
    statistical Method
    t-test, 1 sided
  3. group Description
    Week 9
    group Ids
    1. OG000
    2. OG002
    non Inferiority Type
    SUPERIORITY
    p Value
    0.90
    p Value Comment
    One-sided significance level 0.05
    statistical Method
    t-test, 1 sided
  4. group Description
    Week 9
    group Ids
    1. OG001
    2. OG002
    non Inferiority Type
    SUPERIORITY
    p Value
    0.79
    p Value Comment
    One-sided significance level 0.05
    statistical Method
    t-test, 1 sided
Complete source fields
analyses
  1. group Description
    Week 5
    group Ids
    1. OG000
    2. OG002
    non Inferiority Type
    SUPERIORITY
    p Value
    0.41
    p Value Comment
    One-sided significance level 0.05
    statistical Method
    t-test, 1 sided
  2. group Description
    Week 5
    group Ids
    1. OG001
    2. OG002
    non Inferiority Type
    SUPERIORITY
    p Value
    0.60
    p Value Comment
    One-sided significance level 0.05
    statistical Method
    t-test, 1 sided
  3. group Description
    Week 9
    group Ids
    1. OG000
    2. OG002
    non Inferiority Type
    SUPERIORITY
    p Value
    0.90
    p Value Comment
    One-sided significance level 0.05
    statistical Method
    t-test, 1 sided
  4. group Description
    Week 9
    group Ids
    1. OG001
    2. OG002
    non Inferiority Type
    SUPERIORITY
    p Value
    0.79
    p Value Comment
    One-sided significance level 0.05
    statistical Method
    t-test, 1 sided
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        7.27
        value
        3.35
      2. group Id
        OG001
        spread
        5.82
        value
        2.81
      3. group Id
        OG002
        spread
        6.00
        value
        3.08
    denoms
    1. counts
      1. group Id
        OG000
        value
        65
      2. group Id
        OG001
        value
        59
      3. group Id
        OG002
        value
        61
      units
      Participants
    title
    Week 5
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        6.51
        value
        2.05
      2. group Id
        OG001
        spread
        4.72
        value
        2.72
      3. group Id
        OG002
        spread
        6.93
        value
        3.58
    denoms
    1. counts
      1. group Id
        OG000
        value
        65
      2. group Id
        OG001
        value
        60
      3. group Id
        OG002
        value
        60
      units
      Participants
    title
    Week 9
denoms
  1. counts
    1. group Id
      OG000
      value
      79
    2. group Id
      OG001
      value
      74
    3. group Id
      OG002
      value
      76
    units
    Participants
description
The PROMIS Global Satisfaction with Sex Life subscore measures self-reported global satisfaction, interest, and interference in sexual health over the past 7 days. Possible scores range from 3 to 30, with higher scores indicating more satisfaction with sex life. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased satisfaction. This score is referred to as the "PROMIS sexual desire and satisfaction measure" in the protocol.
dispersion Type
Standard Deviation
groups
  1. description
    One Bupropion 150 mg XL capsule PO in a.m. daily for one week; one Bupropion 150 mg XL capsule and one placebo capsule PO in a.m. daily for 8 weeks; one placebo capsule daily PO in a.m. for one 1 week (titration off).
    id
    OG000
    title
    Bupropion 150 mg
  2. description
    One Bupropion 150 mg XL capsule PO in a.m. daily for one week; two Bupropion 150 mg XL capsules PO in a.m. daily for 8 weeks (300 mg target dose); one Bupropion 150 mg XL capsule PO in a.m. daily for 1 week (titration off)
    id
    OG001
    title
    Bupropion 300 mg
  3. description
    One placebo capsule PO in a.m. daily for 1 week; two placebo capsules PO in a.m. daily for 8 weeks; one placebo capsule PO in a.m. daily for 1 week (titration off)
    id
    OG002
    title
    Placebo
param Type
MEAN
population Description
Eligible with baseline data
reporting Status
POSTED
time Frame
Baseline (prior to randomization) and 5 and 9 weeks from start of study treatment (within 21 days of randomization)
title
Change From Baseline in the PROMIS Global Satisfaction With Sex Life Subscore of Sexual Function and Satisfaction Measure ("Sexual Desire and Satisfaction")
type
SECONDARY
unit Of Measure
units on a scale

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice